Cystic fibrosis is a genetic disease that affects about 30,000 adults and children in the United States. It causes life-threatening lung infections and serious digestive complications. More than 10 million Americans are symptomless carriers of the CF gene.
GeneGo develops systems biology technology for life science research. The original computational MetaDiscovery(TM) platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo's flagship product, MetaCore 5.0(TM), assists pharmaceutical scientists in the areas of target selection and validation, identification of biomarkers for disease states and toxicology. The second product, MetaDrug2.0(TM) is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase(TM) represents the knowledge base for MetaCore. For more information, please visit the company's web site at http://www.genego.com. MetaCore(TM), MetaBase(TM), MetaDrug(TM), MetaLink(TM), MetaDiscovery(TM), MetaTox(TM), MetaMiner(TM) and 1-2-3 Workflow(TM) are trademarks of GeneGo, Inc.
About the Cystic Fibrosis Foundation
The Cystic Fibrosis Foundation is the leading organization devoted to
curing and controlling cystic fibrosis. Headquartered in Bethesda, Md., the
Foundation funds CF research, has 80 chapter and branch offices throughout
the country, and supports and
|SOURCE GeneGo, Inc.|
Copyright©2007 PR Newswire.
All rights reserved